Chimerix, Inc. (CMRX)

Market Cap	797.33M
Revenue (ttm)	212,000
Net Income (ttm)	-88.39M
Shares Out	93.80M
EPS (ttm)	-0.99
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	835,346
Open	8.50
Previous Close	8.50
Day's Range	8.50 - 8.51
52-Week Range	0.75 - 8.53
Beta	0.32
Analysts	Hold
Price Target	8.51 (+0.12%)
Earnings Date	Mar 21, 2025

About CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 11, 2013
• Employees: 72
• Stock Exchange: NASDAQ
• Ticker Symbol: CMRX
• Website: https://www.chimerix.com

Financial Performance

In 2024, Chimerix's revenue was $212,000, a decrease of -34.57% compared to the previous year's $324,000. Losses were -$88.39 million, 7.66% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for CMRX stock is "Hold." The 12-month stock price forecast is $8.51, which is an increase of 0.12% from the latest price.

Price Target

$8.51

(0.12% upside)

Analyst Consensus: Hold